DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F. et al.
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Haematologica 2016;
101: 821-9
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.